clostridium botulinum type a toxin-haemagglutinin complex: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
clostridium botulinum type a toxin-haemagglutinin complex: clinical details
Prescribing considerations
- Confirm that the indication is licensed for this product and that the injector has relevant expertise and equipment.
- Do not convert units from another botulinum toxin product.
- Assess swallowing, respiratory and neuromuscular function, local muscle weakness or atrophy, falls risk, bleeding tendency, injection-site inflammation and previous reactions.
- Do not use for spasticity caused by a fixed contracture.
- For neurogenic detrusor overactivity, confirm regular clean intermittent catheterisation and plan for urinary and autonomic complications.
Contraindications and cautions
- Known hypersensitivity to the active substance or an excipient.
- Urinary tract infection at the time of treatment for neurogenic detrusor overactivity.
Monitoring
- Warn patients and carers about delayed toxin-spread symptoms and the need for immediate emergency assessment.
- Review local weakness, swallowing, breathing, vision and functional effects relevant to the injection site.
- For bladder treatment, monitor for urinary infection, haematuria and autonomic dysreflexia.
- Record the product name and batch number for biological traceability.
- Consider neutralising antibodies if response deteriorates substantially despite technically appropriate treatment.
Clinical pharmacology
Presynaptic uptake into cholinergic nerve endings disrupts calcium-mediated acetylcholine release, reducing endplate potential and producing local chemodenervation. Recovery follows gradual restoration of functional nerve terminals.
Formulation and product differences
- Powder for solution for injection containing human albumin and lactose.
- Reconstituted with preservative-free sodium chloride solution and used as a clear, colourless solution.
- Routes and preparation differ by indication.
- Each vial is single-use and the prepared product is for one patient during one session.
- Product-specific biological units are not interchangeable with those of other botulinum toxins.
clostridium botulinum type a toxin-haemagglutinin complex preparations and strengths
Injection
Route: Parenteral
Strengths: 300 units, 500 units
clostridium botulinum type a toxin-haemagglutinin complex interactions
Medicines affecting nerves, muscles or procedural bleeding require particular review.
Aminoglycoside antibiotics, such as gentamicin, tobramycin or amikacin
They can enhance interference with neuromuscular transmission and increase unwanted muscle weakness.
Non-depolarising neuromuscular blockers
The neuromuscular-blocking effect may increase, so anaesthetic and treating teams need to know about recent treatment.
Muscle relaxants
Combined effects may cause excessive or more widespread weakness.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.